Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The transaction represents a total equity value of up to $1.5 billion and is expected to close in the first quarter of 2025.
Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion